Logo image of CATB

Catabasis Pharma (CATB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CATB -

8.54
-0.64 (-6.97%)
Last: 9/8/2021, 9:06:56 PM
8.63
+0.09 (+1.05%)
After Hours: 9/8/2021, 9:06:56 PM
Fundamental Rating

1

Taking everything into account, CATB scores 1 out of 10 in our fundamental rating. CATB was compared to 530 industry peers in the Biotechnology industry. While CATB seems to be doing ok healthwise, there are quite some concerns on its profitability. CATB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CATB has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -140.05%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CATB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for CATB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -7.63, we must say that CATB is in the distress zone and has some risk of bankruptcy.
CATB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.63
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 35.12 indicates that CATB has no problem at all paying its short term obligations.
A Quick Ratio of 35.12 indicates that CATB has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 35.12
Quick Ratio 35.12

More info and screens

0

3. Growth

3.1 Past

CATB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -175.70%.
EPS 1Y (TTM)-175.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CATB will show a decrease in Earnings Per Share. The EPS will decrease by -0.87% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-561.19%
EPS Next 2Y11.52%
EPS Next 3Y8.32%
EPS Next 5Y-0.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CATB Yearly Revenue VS EstimatesCATB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 100K 200K 300K
CATB Yearly EPS VS EstimatesCATB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CATB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CATB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CATB Price Earnings VS Forward Price EarningsCATB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.54
CATB Per share dataCATB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.52%
EPS Next 3Y8.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CATB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Catabasis Pharma

NASDAQ:CATB (9/8/2021, 9:06:56 PM)

After market: 8.63 +0.09 (+1.05%)

8.54

-0.64 (-6.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.1%
Inst Owner Change-86.63%
Ins Owners125.25%
Ins Owner Change0%
Market Cap33.34M
Revenue(TTM)N/A
Net Income(TTM)-197.39M
Analysts100
Price Target24.23 (183.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB N/A
EV/EBITDA 0.54
EPS(TTM)-5.9
EYN/A
EPS(NY)-3.2
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS9.51
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -140.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 35.12
Quick Ratio 35.12
Altman-Z -7.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-175.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-561.19%
EPS Next 2Y11.52%
EPS Next 3Y8.32%
EPS Next 5Y-0.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Catabasis Pharma / CATB FAQ

What is the fundamental rating for CATB stock?

ChartMill assigns a fundamental rating of 2 / 10 to CATB.


Can you provide the valuation status for Catabasis Pharma?

ChartMill assigns a valuation rating of 3 / 10 to Catabasis Pharma (CATB). This can be considered as Overvalued.


What is the profitability of CATB stock?

Catabasis Pharma (CATB) has a profitability rating of 1 / 10.


What is the earnings growth outlook for Catabasis Pharma?

The Earnings per Share (EPS) of Catabasis Pharma (CATB) is expected to decline by -561.19% in the next year.